Cardiff Oncology Free Cash Flow Per Share Growth & History (CRDF)
Cardiff Oncology's free cash flow per share was -$0.57 for fiscal 2025.
View full Cardiff Oncology company overviewCardiff Oncology annual free cash flow per share history
| Fiscal year | Period ended | Free cash flow per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | -$0.57 | $0.22 | — |
| 2024 | 2024-12-31 | -$0.79 | -$0.09 | — |
| 2023 | 2023-12-31 | -$0.70 | $0.09 | — |
| 2022 | 2022-12-31 | -$0.80 | -$0.20 | — |
| 2021 | 2021-12-31 | -$0.60 | $0.20 | — |
| 2020 | 2020-12-31 | -$0.79 | $1.44 | — |
| 2019 | 2019-12-31 | -$2.23 | $3.43 | — |
| 2018 | 2018-12-31 | -$5.67 | $42.88 | — |
| 2017 | 2017-12-31 | -$48.54 | $27.49 | — |
| 2016 | 2016-12-31 | -$76.03 | -$9.09 | — |
| 2015 | 2015-12-31 | -$66.94 | -$17.08 | — |
| 2014 | 2014-12-31 | -$49.86 | -$16.07 | — |
| 2013 | 2013-12-31 | -$33.79 | -$5.08 | — |
| 2012 | 2012-12-31 | -$28.70 | -$14.38 | — |
| 2011 | 2011-12-31 | -$14.32 | — | — |
Cardiff Oncology quarterly free cash flow per share
| Fiscal quarter | Period ended | Free cash flow per share | Change | YoY change |
|---|---|---|---|---|
| Q3 2025 | 2025-09-30 | -$0.16 | $0.06 | — |
| Q3 2024 | 2024-09-30 | -$0.22 | -$0.04 | — |
| Q2 2024 | 2024-06-30 | -$0.21 | -$0.04 | — |
| Q1 2024 | 2024-03-31 | -$0.18 | $0.02 | — |
| Q3 2023 | 2023-09-30 | -$0.19 | -$0.00 | — |
| Q2 2023 | 2023-06-30 | -$0.17 | -$0.00 | — |
| Q1 2023 | 2023-03-31 | -$0.19 | $0.05 | — |
| Q3 2022 | 2022-09-30 | -$0.18 | -$0.04 | — |
| Q2 2022 | 2022-06-30 | -$0.16 | -$0.05 | — |
| Q1 2022 | 2022-03-31 | -$0.24 | -$0.08 | — |
| Q3 2021 | 2021-09-30 | -$0.14 | $0.02 | — |
| Q2 2021 | 2021-06-30 | -$0.11 | $0.19 | — |
| Q1 2021 | 2021-03-31 | -$0.16 | $0.18 | — |
| Q3 2020 | 2020-09-30 | -$0.16 | $0.40 | — |
| Q2 2020 | 2020-06-30 | -$0.30 | $0.36 | — |
| Q1 2020 | 2020-03-31 | -$0.34 | $0.48 | — |
| Q3 2019 | 2019-09-30 | -$0.56 | $0.45 | — |
| Q2 2019 | 2019-06-30 | -$0.66 | $1.97 | — |
| Q1 2019 | 2019-03-31 | -$0.82 | $2.90 | — |
| Q3 2018 | 2018-09-30 | -$1.01 | $12.24 | — |
| Q2 2018 | 2018-06-30 | -$2.63 | $8.07 | — |
| Q1 2018 | 2018-03-31 | -$3.72 | $16.67 | — |
| Q4 2017 | 2017-12-31 | -$6.03 | $15.19 | — |
| Q3 2017 | 2017-09-30 | -$13.25 | $3.76 | — |
| Q2 2017 | 2017-06-30 | -$10.70 | $9.48 | — |
| Q1 2017 | 2017-03-31 | -$20.39 | -$2.81 | — |
| Q4 2016 | 2016-12-31 | -$21.22 | -$2.34 | — |
| Q3 2016 | 2016-09-30 | -$17.01 | -$2.64 | — |
| Q2 2016 | 2016-06-30 | -$20.18 | -$2.95 | — |
| Q1 2016 | 2016-03-31 | -$17.59 | -$1.15 | — |
| Q4 2015 | 2015-12-31 | -$18.88 | -$3.66 | — |
| Q3 2015 | 2015-09-30 | -$14.37 | -$1.00 | — |
| Q2 2015 | 2015-06-30 | -$17.23 | -$7.07 | — |
| Q1 2015 | 2015-03-31 | -$16.43 | -$5.32 | — |
| Q4 2014 | 2014-12-31 | -$15.21 | -$7.85 | — |
| Q3 2014 | 2014-09-30 | -$13.37 | -$4.07 | — |
| Q2 2014 | 2014-06-30 | -$10.16 | -$0.91 | — |
| Q1 2014 | 2014-03-31 | -$11.11 | -$3.12 | — |
| Q4 2013 | 2013-12-31 | -$7.37 | -$0.63 | — |
| Q3 2013 | 2013-09-30 | -$9.30 | -$1.74 | — |
| Q2 2013 | 2013-06-30 | -$9.25 | -$1.27 | — |
| Q1 2013 | 2013-03-31 | -$7.99 | -$6.58 | — |
| Q4 2012 | 2012-12-31 | -$6.74 | — | — |
| Q3 2012 | 2012-09-30 | -$7.56 | -$4.74 | — |
| Q2 2012 | 2012-06-30 | -$7.98 | -$4.45 | — |
| Q1 2012 | 2012-03-31 | -$1.42 | $980.56 | — |
| Q3 2011 | 2011-09-30 | -$2.82 | — | — |
| Q2 2011 | 2011-06-30 | -$3.53 | — | — |
| Q1 2011 | 2011-03-31 | -$981.98 | — | — |
Cardiff Oncology free cash flow per share trends
Over the last five fiscal years, Cardiff Oncology's free cash flow per share increased from -$0.79 to -$0.57, a change of $0.22. The latest reported quarter, Q3 2025, shows -$0.16.
What free cash flow per share means
Free cash flow per share estimates the free cash flow generated for each weighted-average common share. It combines operating cash generation, capital spending, and the share base into a per-share measure that can be compared over time.
How free cash flow per share is calculated
TickerStat calculates free cash flow as operating cash flow minus capital expenditures, then divides it by basic weighted-average shares for the aligned fiscal period. Reliable filing-derived share counts are used when a filer omits the direct weighted-average-share fact. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cardiff Oncology source filings ↗